Patients Cope With Intense Emotions After Clinical Trial Withdrawal
When withdrawing from a clinical trial, patients experience a spectrum of emotions ranging from regret, urgency, frustration—and trust in their healthcare professionals, like oncology nurses, according to the results of a study published in JAMA Network Open.
Not Eligible for Trials? Expanded Access May Give Patients Options for Investigational Products
The U.S. Food and Drug Administration’s (FDA’s) expanded access program is a pathway for providers to request using an investigational medical product to treat a patient with an immediately life-threatening or serious disease or condition outside of clinical trials when no comparable or satisfactory alternative therapy options are available. FDA’s Project Facilitate, a comprehensive program within FDA’s Oncology Center of Excellence, makes the pathway more accessible by assisting oncology healthcare professionals in submitting single-patient oncology expanded access applications.
- Read more about Not Eligible for Trials? Expanded Access May Give Patients Options for Investigational Products
- Add new comment
Nursing Roles in Clinical Trials
Clinical trials provide evidence to support what you do in your work as a nurse every day. They are tools to discover new therapies and identify side effects while considering patient-specific factors like age, comorbidities, race, and sex. They build support for best practices in treatment and patient care.
Joint Strategic Planning Allows ONS Enterprise to Achieve Shared Goals
The ONS, Oncology Nursing Foundation, and Oncology Nursing Certification Corporation Boards of Directors all held their in-person meetings concurrently in early November. One day was committed to joint strategic alignment work with executive leadership staff. Consultants led the group through a strategic alignment session to identify the top themes across the Enterprise to build overarching goals for the three organizations by early 2022. All of the boards are developing individual strategic plans that will begin in 2023.
- Read more about Joint Strategic Planning Allows ONS Enterprise to Achieve Shared Goals
- Add new comment
FDA Approves Rituximab Plus Chemotherapy for Pediatric Cancer Indications
On December 2, 2021, the U.S. Food and Drug Administration (FDA) approved rituximab (Rituxan®) in combination with chemotherapy for pediatric patients aged at least 6 months to 18 years with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.
- Read more about FDA Approves Rituximab Plus Chemotherapy for Pediatric Cancer Indications
- Add new comment
FDA Approves Daratumumab Hyaluronidase-Fihj, Carfilzomib, Dexamethasone for Multiple Myeloma
On November 30, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro™), carfilzomib (Kyprolis®), and dexamethasone for adult patients with relapsed or refractory multiple myeloma who received one to three prior lines of therapy.
- Read more about FDA Approves Daratumumab Hyaluronidase-Fihj, Carfilzomib, Dexamethasone for Multiple Myeloma
- Add new comment
CMS, HHS Issue Emergency Regulation Requiring COVID-19 Vaccination for Healthcare Workers
In an effort to protect patients and control the COVID-19 coronavirus pandemic, the Centers for Medicare and Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS) have issued an interim final rule requiring all staff at certain Medicare- and Medicaid-certified healthcare facilities to be vaccinated against COVID-19.
- Read more about CMS, HHS Issue Emergency Regulation Requiring COVID-19 Vaccination for Healthcare Workers
- Add new comment
Biden Brings Robert Califf Back to FDA
Citing his extensive medical background and leadership experience, in November 2021, President Joe Biden nominated Robert Califf, MD, MACC, adjunct professor of medicine, professor of cardiology, and member of the Duke Clinical Research Institute at the Duke University School of Medicine in Durham, NC, as U.S. Food and Drug Administration (FDA) commissioner. Califf will assume the role once confirmed by the U.S. Senate.
Aileen Anglin
Nurses Must Take the Lead in Tobacco Cessation
Associated with more than a dozen different cancers, tobacco use is the leading cause of cancer and cancer deaths in the United States. The Centers for Disease Control and Prevention (CDC) estimated that 40% of all cancers are linked to tobacco use, and it’s responsible for 30% of cancer deaths in the United States and 22% around the world.